Tags

Type your tag names separated by a space and hit enter

Evolving therapies for multiple sclerosis.

Abstract

The introduction of immunomodulatory and immunosuppressive agents for treatment of multiple sclerosis (MS) has forever altered the natural course of this incurable and disabling neurodegenerative disorder. Despite early diagnosis of relapsing-remitting MS and early initiation of therapy, patients still experience breakthrough relapses and progression of their underlying MS pathology. The imperfect effectiveness, side effects, and toxicity of these agents, emphasize the necessity for development of more effective medications with less adverse events. This chapter presents readers with the most current information on the nature, mechanism(s) of action, and side effects of the most promising experimental agents currently under clinical trials. Some of the agents now at different stages of clinical trial have emerged as both safe and promising. The understanding of MS etiology will lead to the development of increasingly specific, safer, and effective treatments for MS by neuroscientists and neurologists.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, Louisiana 71103, USA.

    , , , , , , , , , , ,

    Source

    MeSH

    Animals
    Antibodies, Monoclonal
    Humans
    Immunosuppressive Agents
    Multiple Sclerosis
    Stem Cell Transplantation
    Vaccination
    Vitamin D

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    17531859

    Citation

    Korniychuk, Elena, et al. "Evolving Therapies for Multiple Sclerosis." International Review of Neurobiology, vol. 79, 2007, pp. 571-88.
    Korniychuk E, Dempster JM, O'Connor E, et al. Evolving therapies for multiple sclerosis. Int Rev Neurobiol. 2007;79:571-88.
    Korniychuk, E., Dempster, J. M., O'Connor, E., Alexander, J. S., Kelley, R. E., Kenner, M., ... Minagar, A. (2007). Evolving therapies for multiple sclerosis. International Review of Neurobiology, 79, pp. 571-88.
    Korniychuk E, et al. Evolving Therapies for Multiple Sclerosis. Int Rev Neurobiol. 2007;79:571-88. PubMed PMID: 17531859.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Evolving therapies for multiple sclerosis. AU - Korniychuk,Elena, AU - Dempster,John M, AU - O'Connor,Eileen, AU - Alexander,J Steven, AU - Kelley,Roger E, AU - Kenner,Meghan, AU - Menon,Uma, AU - Misra,Vivek, AU - Hoque,Romy, AU - Gonzalez-Toledo,Eduardo, AU - Schwendimann,Robert N, AU - Smith,Stacy, AU - Minagar,Alireza, PY - 2007/5/29/pubmed PY - 2007/8/3/medline PY - 2007/5/29/entrez SP - 571 EP - 88 JF - International review of neurobiology JO - Int. Rev. Neurobiol. VL - 79 N2 - The introduction of immunomodulatory and immunosuppressive agents for treatment of multiple sclerosis (MS) has forever altered the natural course of this incurable and disabling neurodegenerative disorder. Despite early diagnosis of relapsing-remitting MS and early initiation of therapy, patients still experience breakthrough relapses and progression of their underlying MS pathology. The imperfect effectiveness, side effects, and toxicity of these agents, emphasize the necessity for development of more effective medications with less adverse events. This chapter presents readers with the most current information on the nature, mechanism(s) of action, and side effects of the most promising experimental agents currently under clinical trials. Some of the agents now at different stages of clinical trial have emerged as both safe and promising. The understanding of MS etiology will lead to the development of increasingly specific, safer, and effective treatments for MS by neuroscientists and neurologists. SN - 0074-7742 UR - https://www.unboundmedicine.com/medline/citation/17531859/full_citation L2 - https://linkinghub.elsevier.com/retrieve/pii/S0074-7742(07)79025-6 DB - PRIME DP - Unbound Medicine ER -